Evaluating the Efficacy of Oral Semaglutide in Chinese Patients with Type 2 Diabetes by Baseline Characteristics-Post Hoc Analysis of PIONEER 11 and 12

被引：0
|
作者：
Ji, Linong
Yuan, Guoyue
Liu, Jun
Zhang, Bingjie
Liu, Wenyan
Shen, Zewei
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-752-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
752-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial
    Wang, Weiqing
    Bain, Stephen C.
    Bian, Fang
    Chen, Rui
    Gabery, Sanaz
    Huang, Shan
    Jensen, Thomas B.
    Luo, Bifen
    Yuan, Guoyue
    Ning, Guang
    DIABETOLOGIA, 2024, 67 (09) : 1783 - 1799
  • [22] Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis
    Zhong, Ping
    Zeng, Hai
    Huang, Miaochun
    He, Guoxin
    Chen, Zhixia
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [23] PIONEER 11: Efficacy and safety of oral semaglutide versus placebo in predominantly Chinese patients with T2D treated with diet and exercise
    Wang, W.
    Chen, R.
    Davies, A. Lloyd
    Guo, J.
    Jensen, T. Bo
    Li, Y.
    Luo, B.
    Ye, X.
    Zhang, K.
    Ning, G.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [24] Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes
    Mahzari, Moeber Mohammed
    Alluhayyan, Omar Buraykan
    Almutairi, Mahdi Hamad
    Bayounis, Mohammed Abdullah
    Alrayani, Yazeed Hasan
    Omair, Amir A.
    Alshahrani, Awad Saad
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2024, 36
  • [25] Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis
    Zhang, Lin
    Hua, Zixin
    Fang, Zhenwei
    Wei, Juanjuan
    Lin, Yang
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (10): : 1312 - 1325
  • [26] Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials
    Verma, Subodh
    David, Jens-Peter
    Leiter, Lawrence A.
    Michelsen, Marie Mide
    Rasmussen, Soren
    Bhatt, Deepak L.
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2388 - 2392
  • [27] Post Hoc Analysis of SURPASS-1 to-5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
    De Block, Christophe
    Peleshok, Jennifer
    Wilding, John P. H.
    Kwan, Anita Y. M.
    Rasouli, Neda
    Maldonado, Juan M.
    Wysham, Carol
    Liu, Minzhi
    Aleppo, Grazia
    Benneyworth, Brian D.
    DIABETES THERAPY, 2025, 16 (01) : 43 - 71
  • [28] Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial
    Ji, Linong
    Agesen, Rikke M.
    Bain, Stephen C.
    Fu, Fangming
    Gabery, Sanaz
    Geng, Jianlin
    Li, Yiming
    Lu, Yibing
    Luo, Bifen
    Pang, Wuyan
    Tao, Yi
    DIABETOLOGIA, 2024, 67 (09) : 1800 - 1816
  • [29] PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan
    Suzuki, Ryo
    Amadid, Hanan
    Major-Pedersen, Atheline
    Yabe, Daisuke
    JOURNAL OF DIABETES INVESTIGATION, 2024, 15 (08) : 1047 - 1056
  • [30] Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics
    Inokuchi, Tetsuaki
    Fukumoto, Yoshihide
    Lee, Gendai
    Yokomizo, Yoshifumi
    Tanaka, Kokichi
    Chosa, Michiko
    Doi, Masaru
    Tamaki, Noboru
    Goto, Seiichi
    Ichikawa, Kojiro
    Kobayashi, Kazuo
    JOURNAL OF DIABETES INVESTIGATION, 2024, 15 (09) : 1202 - 1210
12345